CareLit Fachartikel

The efficacy and safety of LY2963016 among patients with Type 1 and Type 2 diabetes previously treated with insulin glargine

D Dahl, LB Lacaya, RK Pollom, LL Ilag, JS Zielonka · Diabetologie und Stoffwechsel · 2015 · Heft 04

Dokument
1145078
CareLit-ID
Jahr
2015
Publikation
PDF
nein
Metadaten
DOI
ja
zitierfähig

Bibliografische Angaben

Zeitschrift
Diabetologie und Stoffwechsel
Autor:innen
D Dahl, LB Lacaya, RK Pollom, LL Ilag, JS Zielonka
Ausgabe
Heft 04 / 2015
Seiten
–
Erschienen: 2015-04-29 00:00:00
ISSN
1861-9002
DOI
10.1055/s-0035-1549538

Zusammenfassung

Introduction: We evaluated the treatment effect of LY2963016 insulin glargine (LY IGlar) as compared to insulin glargine (Sanofi-Aventis; IGlar) in a subgroup of patients who reported prestudy treatment with IGlar (prior IGlar) for Type 1 diabetes and Type 2 diabetes in 52-week open-label (ELEMENT-1) and 24-week double-blind (ELEMENT-2) randomised studies. Methods: Both studies used unit-to-unit dose conversions from prestudy IGlar to study LY IGlar or IGlar then treat-to-target titration. Primary efficacy (defined as change in HbA1c from baseline to the 24-week endpoint), other efficacy, and select safety outco…

Schlagworte

Iglar Treatment Efficacy Insulin Safety Patients Element-1 Outcomes Diabetes Glargine Prestudy Element-2 Diabetologie und Stoffwechsel